Citadel Advisors
CRDF icon

Citadel Advisors’s Cardiff Oncology CRDF Stock Holding History

Citadel Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,500
Closed -$96.9K – 13146
2025
Q4 		$96.9K Buy
34,500
+15,900
+85% +$36.9K ﹤0.01% 11669
2025
Q3 		$38.3K Sell
18,600
-58,100
-76% -$161K ﹤0.01% 12310
2025
Q2 		$242K Buy
76,700
+20,400
+36% +$62.2K ﹤0.01% 10287
2025
Q1 		$177K Sell
56,300
-33,300
-37% -$132K ﹤0.01% 10624
2024
Q4 		$389K Buy
89,600
+63,100
+238% +$197K ﹤0.01% 9113
2024
Q3 		$70.8K Sell
26,500
-11,400
-30% -$26.9K ﹤0.01% 11543
2024
Q2 		$84.1K Buy
37,900
+18,200
+92% +$68.6K ﹤0.01% 11152
2024
Q1 		$105K Buy
19,700
+18,600
+1,691% +$49.4K ﹤0.01% 11288
2023
Q4 		$1.63K Sell
1,100
-7,400
-87% -$8.95K ﹤0.01% 13801
2023
Q3 		$11.8K Buy
+8,500
New +$14.3K ﹤0.01% 12989
2023
Q2 		– Sell
-11,600
Closed -$19.1K – 14448
2023
Q1 		$19.1K Sell
11,600
-10,000
-46% -$17.2K ﹤0.01% 13099
2022
Q4 		$30.2K Sell
21,600
-49,500
-70% -$70.9K ﹤0.01% 12741
2022
Q3 		$109K Buy
71,100
+6,500
+10% +$15.6K ﹤0.01% 11009
2022
Q2 		$142K Sell
64,600
-20,600
-24% -$34.5K ﹤0.01% 11038
2022
Q1 		$211K Buy
85,200
+3,800
+5% +$13.4K ﹤0.01% 11396
2021
Q4 		$489K Buy
81,400
+8,400
+12% +$50.1K ﹤0.01% 9752
2021
Q3 		$486K Buy
73,000
+28,300
+63% +$178K ﹤0.01% 9938
2021
Q2 		$297K Sell
44,700
-16,900
-27% -$143K ﹤0.01% 11293
2021
Q1 		$570K Sell
61,600
-1,600
-3% -$19.4K ﹤0.01% 9396
2020
Q4 		$1.14M Buy
63,200
+6,900
+12% +$121K ﹤0.01% 6534
2020
Q3 		$799K Buy
+56,300
New +$372K ﹤0.01% 6424
2016
Q4 		– Sell
-144
Closed -$47K – 7309
2016
Q3 		$47K Buy
+144
New +$52.5K ﹤0.01% 6867

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Citadel Advisors's CRDF Position: Q1 2026 in Review

Citadel Advisors increased its Cardiff Oncology (CRDF) stake by 6.2% in Q1 2026, buying an estimated $15.2K and bringing the position to 125,566 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #11391.

Citadel Advisors first reported a position in CRDF in Q1 2014 and has held it in 27 quarters since. The position peaked at $15.6M in Q4 2020. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Citadel Advisors held 125,566 shares of Cardiff Oncology worth $203K as of Q1 2026.
  • Citadel Advisors bought 7,378 Cardiff Oncology shares in Q1 2026, an estimated $15.2K.
  • Cardiff Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11391 holding.
  • Citadel Advisors first reported a position in Cardiff Oncology in Q1 2014 and has held it in 27 quarters since.
  • Citadel Advisors's Cardiff Oncology position peaked at $15.6M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.